a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement.
The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria.
a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.
Company Details
- Employees
- 20
- Address
- Dr.-Bohr-Gasse 7, Vienna,wien 1030,austria
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- aheadbio.com
- Keywords
- into unified.
- HQ
- Vienna, Wien
A:head Bio Ag Questions
A:Head Bio Ag's website is aheadbio.com
A:Head Bio Ag's LinkedIn profile is https://at.linkedin.com/company/aheadbio
A:Head Bio Ag has
20 employees.
View email and phone details for 20
employees at A:Head Bio Ag.
A:Head Bio Ag's industry is
Pharmaceutical Manufacturing
A:Head Bio Ag's top competitors are
Oncoone,
Sarcura,
Viverita Therapeutics,
Biotech Austria,
Proxygen,
Heartbeat.bio Ag,
Myllia Biotechnology,
Lexogen,
Ribbon Bio,
Hookipa Pharma Inc..
A:Head Bio Ag's categories are Pharmaceutical Manufacturing
